Abstract
Alzheimer's disease (AD) and Parkinson's disease (PD) are two of the most common neurodegenerative disorders, each with distinct clinical and pathological features, yet sharing significant overlaps that complicate diagnosis and management. AD is primarily characterized by cognitive decline stemming from amyloid-beta plaques and tau tangles, while PD is defined by motor dysfunction caused by alpha-synuclein-containing Lewy bodies. Despite these differences, both diseases exhibit overlapping cognitive, neuropsychiatric, and motor symptoms, along with shared underlying mechanisms like neuroinflammation and abnormal protein aggregation. This article explores these overlapping features, including memory and executive function deficits, neuropsychiatric symptoms such as depression and apathy, and motor signs like bradykinesia and rigidity. It also discusses the diagnostic challenges arising from these overlaps, highlighting the limitations of current tools and the promise of a multi-modal diagnostic strategy that integrates clinical evaluation, advanced neuroimaging, and emerging biomarkers. The review concludes by outlining future research directions, emphasizing the potential of advanced imaging, early detection of dual pathologies, and the development of integrated therapeutic approaches to enable precision medicine for these complex disorders.
References
Aborode, A. T., Emmanuel, O. A., Onifade, I. A., Olotu, E., Otorkpa, O. J., Mehmood, Q., Abdulai, S. I., Jamiu, A., Osinuga, A., Oko, C. I., Fakorede, S., Mangdow, M., Babatunde, O., Olapade, Z., Victoria, A. G., Salami, A., Usman, I. A., Agboli, V. I., & Adesola, R. O. (2025). The role of machine learning in discovering biomarkers and predicting treatment strategies for neurodegenerative diseases: A narrative review. NeuroMarkers., 2(1), 100034.
https://doi.org/10.1016/j.neumar.2024.100034
Andrade-Guerrero, J., Martínez-Orozco, H., Villegas-Rojas, M. M., Santiago-Balmaseda, A., Delgado-Minjares, K. M., Pérez-Segura, I., Baéz-Cortés, M. T., Del Toro-Colin, M. A., Guerra-Crespo, M., Arias-Carrión, O., Diaz-Cintra, S., & Soto-Rojas, L. O. (2024). Alzheimer's Disease: Understanding Motor Impairments. Brain sciences, 14(11), 1054.
https://doi.org/10.3390/brainsci14111054
Angel Pinto, M. J., García Cordero, I., Dorman, G., Mizraji, G., Anastassiadis, C., Gershanik, O., & Couto, B. (2026). Amyloid and Tau Co-pathology in Parkinson Disease and Atypical Parkinsonism. Current neurology and neuroscience reports, 26(1), 21.
https://doi.org/10.1007/s11910-026-01488-0
Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. The Lancet, 397(10291), 2284–2303.
https://doi.org/10.1016/s0140-6736(21)00218-x
Bronnick, K., Emre, M., Lane, R., Tekin, S., & Aarsland, D. (2007). Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. Journal of neurology, neurosurgery, and psychiatry, 78(10), 1064–1068.
https://doi.org/10.1136/jnnp.2006.108076
Cantone, M., & Sacco, L. (2023). Editorial: Highlights in Alzheimer's and Parkinson's disease. Frontiers in Human Neuroscience, 17, Article 1238525.
https://doi.org/10.3389/fnhum.2023.1238525
Chan, P. C., Lee, H. H., Hong, C. T., Hu, C. J., & Wu, D. (2018). REM Sleep Behavior Disorder (RBD) in Dementia with Lewy Bodies (DLB). Behavioural neurology, 2018, 9421098.
https://doi.org/10.1155/2018/9421098
Chung, S. J., Lee, J. J., Ham, J. H., Lee, P. H., & Sohn, Y. H. (2016). Apathy and striatal dopamine defects in non-demented patients with Parkinson's disease. Parkinsonism & related disorders, 23, 62–65.
https://doi.org/10.1016/j.parkreldis.2015.12.003
Crowley, S. J., Banan, G., Amin, M., Tanner, J. J., Hizel, L., Nguyen, P., Brumback, B., Rodriguez, K., McFarland, N., Bowers, D., Ding, M., Mareci, T. A., & Price, C. C. (2021). Statistically Defined Parkinson's Disease Executive and Memory Cognitive Phenotypes: Demographic, Behavioral, and Structural Neuroimaging Comparisons. Journal of Parkinson's disease, 11(1), 283–297.
https://doi.org/10.3233/JPD-202166
Detka, J., Płachtij, N., Strzelec, M., Manik, A., & Sałat, K. (2024). p38α Mitogen-Activated Protein Kinase-An Emerging Drug Target for the Treatment of Alzheimer's Disease. Molecules (Basel, Switzerland), 29(18), 4354.
https://doi.org/10.3390/molecules29184354
Husa, A. P., Rannikko, I., Moilanen, J., Haapea, M., Murray, G. K., Barnett, J., Jones, P. B., Isohanni, M., Koponen, H., Miettunen, J., & Jääskeläinen, E. (2014). Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - An observational 9-year follow-up study. Schizophrenia research, 158(1-3), 134–141.
https://doi.org/10.1016/j.schres.2014.06.035
Jack, C. R., Jr, Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., Molinuevo, J. L., Okonkwo, O. C., Pani, L., Rafii, M. S., Scheltens, P., Siemers, E., Snyder, H. M., Sperling, R., Teunissen, C. E., & Carrillo, M. C. (2024). Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & dementia : the journal of the Alzheimer's Association, 20(8), 5143–5169.
https://doi.org/10.1002/alz.13859
Kang, H. S., Myung, W., Na, D. L., Kim, S. Y., Lee, J. H., Han, S. H., Choi, S. H., Kim, S., Kim, S., & Kim, D. K. (2014). Factors associated with caregiver burden in patients with Alzheimer's disease. Psychiatry investigation, 11(2), 152–159.
https://doi.org/10.4306/pi.2014.11.2.152
Kim, H., Le, B., Goshi, N., Zhu, K., Grodzki, A. C., Lein, P. J., Zhao, M., & Seker, E. (2024). Primary cortical cell tri-culture to study effects of amyloid-β on microglia function and neuroinflammatory response. Journal of Alzheimer's disease: JAD, 102(3), 730–741.
https://doi.org/10.1177/13872877241291142
Lawrence, B. J., Gasson, N., Kane, R., Bucks, R. S., & Loftus, A. M. (2014). Activities of daily living, depression, and quality of life in Parkinson's disease. PloS one, 9(7), e102294.
https://doi.org/10.1371/journal.pone.0102294
Luca, A., Luca, M., Ferri, R., Lanza, G., & Serretti, A. (2026). Neuropsychiatric and behavioural correlates of sundowning in Alzheimer's disease. International journal of psychiatry in clinical practice, 1–7. Advance online publication.
https://doi.org/10.1080/13651501.2026.2642681
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attix, D. K., Ballard, C. G., Bayston, A., Beach, T. G., Blancato, F., Bonanni, L., Bras, J., Brundin, P., Burn, D. J., Chen-Plotkin, A., Duda, J. E., ... Kosaka, K. (2017). Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology, 89(1), 88–100.
https://doi.org/10.1212/WNL.0000000000004058
Mohan Kumar, D., & Talwar, P. (2025). Amyloid-β, Tau, and α-Synuclein Protein Interactomes as Therapeutic Targets in Neurodegenerative Diseases. Cellular and molecular neurobiology, 45(1), 84.
https://doi.org/10.1007/s10571-025-01604-7
Nakaoku, Y., Ogata, S., Nemoto, K., Kakuta, C., Kiyoshige, E., Teramoto, K., Nakatsuka, K., Ganbaatar, G., Ihara, M., & Nishimura, K. (2025). Combinations of multimodal neuroimaging biomarkers and cognitive test scores to identify patients with cognitive impairment. Frontiers in aging neuroscience, 17, 1650629.
https://doi.org/10.3389/fnagi.2025.1650629
Nik Ramli, N. N., Omar, N., Husin, A., Ismail, Z., & Siran, R. (2015). Preconditioning effect of (S)-3,5-dihydroxyphenylglycine on ischemic injury in middle cerebral artery occluded Sprague-Dawley rats. Neuroscience letters, 588, 137–141.
https://doi.org/10.1016/j.neulet.2014.12.062
Nik Ramli, N. N., & Siran, R. (2015). The neuroprotective effects of (S)-3,5-dihydroxyphenylglycine preconditioning in middle cerebral artery occluded rats: a perspective as a contrivance for stroke. Neural regeneration research, 10(8), 1221–1222.
https://doi.org/10.4103/1673-5374.162748
Okitsu, M., Sugaya, K., Nakata, Y., Kawazoe, T., Ikezawa, J., Okiyama, R., & Takahashi, K. (2023). Degeneration of nigrostriatal dopaminergic neurons in the early to intermediate stage of dementia with Lewy bodies and Parkinson's disease. Journal of the neurological sciences, 449, 120660.
https://doi.org/10.1016/j.jns.2023.120660
Ou, F. S., Michiels, S., Shyr, Y., Adjei, A. A., & Oberg, A. L. (2021). Biomarker Discovery and Validation: Statistical Considerations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 16(4), 537–545.
https://doi.org/10.1016/j.jtho.2021.01.1616
Ozkan, T., Ataoglu, N. E. E., Soke, F., Karakoc, S., & Bora, H. A. T. (2023). Investigation of the relationship between trunk control and balance, gait, functional mobility, and fear of falling in people with Alzheimer's disease. Irish journal of medical science, 192(5), 2401–2408.
https://doi.org/10.1007/s11845-023-03279-9
Pagonabarraga, J., Álamo, C., Castellanos, M., Díaz, S., & Manzano, S. (2023). Depression in Major Neurodegenerative Diseases and Strokes: A Critical Review of Similarities and Differences among Neurological Disorders. Brain sciences, 13(2), 318.
https://doi.org/10.3390/brainsci13020318
Perl, D. P., Olanow, C. W., & Calne, D. (1998). Alzheimer's disease and Parkinson's disease: Distinct entities or extremes of a spectrum of neurodegeneration? Annals of Neurology, 44(S1), S19–S31.
https://doi.org/10.1002/ana.410440705
Pleizier, C. M., van der Vlies, A. E., Koedam, E., Koene, T., Barkhof, F., van der Flier, W. M., Scheltens, P., & Pijnenburg, Y. (2012). Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia. Journal of neurology, neurosurgery, and psychiatry, 83(12), 1145–1148.
https://doi.org/10.1136/jnnp-2012-302437
Röntgen, A., Toprakcioglu, Z., Morris, O. M., & Vendruscolo, M. (2025). Amyloid-β modulates the phase separation and aggregation of α-synuclein. Proceedings of the National Academy of Sciences, 122(29), e2501987122.
https://doi.org/10.1073/pnas.2501987122
Sharma K. (2019). Cholinesterase inhibitors as Alzheimer's therapeutics (Review). Molecular medicine reports, 20(2), 1479–1487.
https://doi.org/10.3892/mmr.2019.10374
Wang, Y., Li, D., Chen, Y., Zhu, S., Jiang, X., Jiang, Y., Gu, R., Shen, B., Zhu, J., Pan, Y., Yan, J., & Zhang, L. (2023). Clinical features of minor hallucinations in different phenotypes of Parkinson's disease: A cross-sectional study. Frontiers in neurology, 14, 1158188.
https://doi.org/10.3389/fneur.2023.1158188
Wolters E. C. (1999). Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology, 52(7 Suppl 3), S10–S13.
Xu, M. M., Hu, D. T., Zhang, Q., Liu, X. G., Li, Z. W., & Lu, L. M. (2025). Sheng li xue bao : [Acta physiologica Sinica], 77(3), 419–431.
https://doi.org/10.13294/j.aps.2025.0049
Yassaghi, Y., Nazerian, Y., Ghasemi, M., Nazerian, A., Sayehmiri, F., Perry, G., & Gholami Pourbadie, H. (2024). Microglial modulation as a therapeutic strategy in Alzheimer's disease: Focus on microglial preconditioning approaches. Journal of cellular and molecular medicine, 28(15), e18554.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Nur Batrisyia Nizam, Nik Nasihah Nik Ramli, Nur Athirah Azlan, Muhammad Danial Che Ramli